Goldstein L B, Hasselblad V, Matchar D B, McCrory D C
Center for Health Policy Research and Education, Duke University, Durham, NC, USA.
Neurology. 1995 Nov;45(11):1965-70. doi: 10.1212/wnl.45.11.1965.
Comparison and meta-analysis of randomized trials of carotid endarterectomy for symptomatic stenosis of the extracranial carotid artery.
Randomized trials (North American Symptomatic Carotid Endarterectomy Trial [NASCET], the European Carotid Surgery Trial [ECST], and the VA Cooperative Study [VACS]) each show that carotid endarterectomy improves outcomes in selected symptomatic patients with high-grade extracranial carotid artery stenosis. Direct comparisons among the studies have not been possible because of differing methodologies, endpoints, and formats of data reporting.
DESIGN/METHODS: Data for specified endpoints and corresponding person-years at risk were obtained for each trial. The rates of nonfatal stroke, nonfatal myocardial infarction, or death for surgically or medically treated patients in the perioperative period (30 days) and thereafter were compared (both including and excluding perioperative events) and then combined using meta-analytic techniques. Data from NASCET and ECST were also analyzed for differences in outcomes by sex.
Event rate estimates (with 95% confidence intervals [95% CI]) for the first 30 days (events per person-year, primarily nonfatal stroke) for medically treated patients were 0.44 (0.22 to 0.76) for NASCET, 0.15 (0.04 to 0.38) for ECST, and 0.27 (0.03 to 0.96) for VACS. For surgically treated patients, the corresponding rates (per person-year) were 0.78 (0.49 to 1.19), 0.63 (0.41 to 0.94), and 1.27 (0.58 to 2.43). Event rates per year after 30 days were higher for medically treated patients (0.20 [0.16 to 0.25] versus 0.08 [0.05 to 0.11] for NASCET; 0.12 [0.10 to 0.15] versus 0.07 [0.06 to 0.09] for ECST; and 0.15 [0.07 to 0.25] versus 0.07 [0.03 to 0.16] for VACS). There were no significant differences among the trials, with an overall benefit for surgical therapy (risk ratio estimate, RR = 0.67, 95% CI = 0.54 to 0.83). There were no significant sex-based differences between NASCET and ECST and the overall benefit was not significantly different for men and women (RR = 0.58, 95% CI = 0.45 to 0.74 for men; RR = 0.84, 95% CI = 0.57 to 1.25 for women).
Adjusting for primary endpoints and duration of follow-up, carotid endarterectomy has a similar benefit for symptomatic patients across trials and a similar benefit for men and women.
对颅外颈动脉症状性狭窄行颈动脉内膜切除术的随机试验进行比较和荟萃分析。
随机试验(北美症状性颈动脉内膜切除术试验[NASCET]、欧洲颈动脉外科试验[ECST]和退伍军人事务部合作研究[VACS])均表明,颈动脉内膜切除术可改善部分有症状的颅外颈动脉高度狭窄患者的预后。由于研究方法、终点指标和数据报告格式不同,无法对这些研究进行直接比较。
设计/方法:获取每个试验中特定终点指标的数据以及相应的风险人年数。比较手术治疗或药物治疗患者围手术期(30天)及之后非致命性卒中、非致命性心肌梗死或死亡的发生率(包括和不包括围手术期事件),然后使用荟萃分析技术进行合并。还分析了NASCET和ECST中按性别划分的预后差异。
药物治疗患者在最初30天的事件发生率估计值(95%置信区间[95%CI],事件/人年,主要是非致命性卒中),NASCET为0.44(0.22至0.76),ECST为0.15(0.04至0.38),VACS为0.27(0.03至0.96)。手术治疗患者相应的发生率(/人年)分别为0.78(0.49至1.19)、0.63(0.41至0.94)和1.27(0.58至2.43)。30天后药物治疗患者每年的事件发生率更高(NASCET:0.20[0.16至0.25]对比0.08[0.05至0.11];ECST:0.12[0.10至0.15]对比0.07[0.06至0.09];VACS:0.15[0.07至0.25]对比0.07[0.03至0.16])。各试验之间无显著差异,手术治疗总体有益(风险比估计值,RR = 0.67,95%CI = 0.54至0.83)。NASCET和ECST之间不存在基于性别的显著差异,男性和女性的总体益处无显著差异(男性RR = 0.58,95%CI = 0.45至0.74;女性RR = 0.84,95%CI = 0.57至1.25)。
调整主要终点指标和随访时间后,颈动脉内膜切除术对各试验中有症状的患者益处相似,对男性和女性的益处也相似。